Summary

The global Vascular access device market is projected to reach USD 9.05 billion by 2030 from USD 5.99 billion in 2024, at a CAGR of 7.1% during the forecast period. This is due to increasing adoption of minimally invasive procedure, as the adoption increases the demand for these devices rises. Additionally, increasing government support to build infrastructure for healthcare is increasing, thus rising the number of hospitals, consequently increasing the demand for the vascular access device. However, the high cost associated with replacement and maintenance of vascular access devices and increasing product recalls are the major restraint to the market. Additionally, the shortage of trained healthcare professionals & limited knowledge about the products is major challenge for the market growth. But is creating a conducive environment for market expansion over the forecast period of 2024-2030.“The central venous access device segment of vascular access device market by type to hold largest position forecast period.”Based on the product, the vascular access device market is divided into central venous access device, peripheral vascular access device, intraosseous access device, and accessories. Among these, in 2023 central venous access device segment account for the largest market share of XX% in vascular access device market. This is due to the rising prevalence of chronic diseases such as cancer, chronic kidney disease. Majority of the cancer patients will be given chemotherapy through these central venous access devices, as the chemotherapy drug are potent and should not be given through peripheral line. Thus, majority of the healthcare professionals prefer these devices. Thus, as the prevalence of these diseases is increasing the need for long-term treatment is rising, consequently increasing the demand for vascular access device market. Additionally, central venous access device has lesser adverse reactions compared to other vascular access devices thus fueling the segmental growth.“The drug administration segment accounts for the largest market share in vascular access device market.”Based on application, the vascular access device market is segmented into drug administration, fluid and nutrition administration, blood transfusion, and diagnostics & testing. The drug administration segment accounts for the largest market share in vascular access device market due to increasing hospitalization for diseases which require long term drug administration such as antibiotic therapy, pain management, chemotherapy and others. For instance, as per a research article, at least 25% of cancer patients undergo chemotherapy, thus increasing demand for implantable ports, peripherally inserted central catheters and tunneled catheters. Additionally, increasing adoption of tunneled catheters for hemodialysis is supporting the market growth, as these devices does not require any prior procedure to insert the device compared to their alternatives. This segment is again divided into chemotherapy and other drug administration. Among these, in 2023, other drug administration segment to hold the largest market share of XX% in vascular access device market by drug application. This is due to increased prevalence of diseases such as infectious diseases, chronic inflammatory diseases, cardiovascular diseases and among others.“Asia Pacific accounted for the second largest share of the vascular access device market by region.”The global vascular access device market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the second largest regional market for vascular access device equipment and is estimated to grow at the highest CAGR during the forecast period. This is due to increasing prevalence of chronic diseases and rising geriatric population across the region. For instance, as per Asia Development Bank, by 2050, one in four people in Asia and Pacific will be over 60 years old thus contributing to the market growth across the forecast period. Asia Pacific region includes Japan, China, India, Australia, South Korea and Rest of Asia Pacific. Among these, China accounts for the largest market share in vascular access device market in 2023. This is due to increasing aging population and rising number of cancer cases and hospital expansions contribute to the growing market. For instance, as per CEIC data, number of hospitals in China increased from 36,976 in 2022 to 38400 in 2023. As the number of hospitals increases, the demand for vascular access devices continues to grow, to support patients..A breakdown of the primary participants referred to for this report is provided below:• By Company Type: Tier 1–40%, Tier 2–30%, and Tier 3– 30%• By Designation: C-level–50%, Director-level–30% and Others–20%• By Region: North America–30%, Europe–25%, Asia Pacific–20%, Latin America- 15%, and Middle east and Africa – 10%Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 =

ページTOPに戻る

Table of Contents

1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 STUDY SCOPE 42
1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD 42
1.3.2 INCLUSIONS & EXCLUSIONS 43
1.3.3 YEARS CONSIDERED 44
1.3.4 CURRENCY CONSIDERED 44
1.4 STAKEHOLDERS 45
1.5 SUMMARY OF CHANGES 45
2 RESEARCH METHODOLOGY 46
2.1 RESEARCH DATA 46
2.1.1 SECONDARY DATA 46
2.1.1.1 Objectives of secondary research 47
2.1.1.2 Key secondary sources 47
2.1.1.3 Key data from secondary sources 48
2.1.2 PRIMARY DATA 48
2.1.2.1 Key primary sources 49
2.1.2.2 Key objectives of primary research 49
2.1.2.3 Key data from primary sources 50
2.1.2.4 Key industry insights 51
2.2 MARKET SIZE ESTIMATION 52
2.2.1 SUPPLY-SIDE ANALYSIS (REVENUE SHARE ANALYSIS) 52
2.2.2 TOP-DOWN APPROACH 53
2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 53
2.2.4 DEMAND-SIDE ANALYSIS 53
2.3 GROWTH FORECAST 54
2.4 DATA TRIANGULATION 57
2.5 MARKET RANKING ANALYSIS 58
2.6 STUDY ASSUMPTIONS 58
2.7 RESEARCH LIMITATIONS 58
2.7.1 METHODOLOGY-RELATED LIMITATIONS 58
2.7.2 SCOPE-RELATED LIMITATIONS 59
2.8 RISK ANALYSIS 59
3 EXECUTIVE SUMMARY 60

4 PREMIUM INSIGHTS 68
4.1 VASCULAR ACCESS DEVICES MARKET OVERVIEW 68
4.2 NORTH AMERICA: VASCULAR ACCESS DEVICES MARKET, BY END USER
AND COUNTRY, 2023 69
4.3 GEOGRAPHIC SNAPSHOT OF VASCULAR ACCESS DEVICES MARKET, 2023 70
4.4 REGIONAL MIX: VASCULAR ACCESS DEVICES MARKET, 2024–2030 (USD MILLION) 71
4.5 VASCULAR ACCESS DEVICES MARKET: EMERGING VS. DEVELOPED MARKETS,
2024 VS. 2030 (USD MILLION) 71
5 MARKET OVERVIEW 72
5.1 INTRODUCTION 72
5.2 MARKET DYNAMICS 72
5.2.1 DRIVERS 73
5.2.1.1 Growing prevalence of lifestyle diseases 73
5.2.1.2 Increasing popularity of chemotherapy procedures
among cancer patients 73
5.2.1.3 Rising use of vascular access devices among pediatric patients 73
5.2.2 RESTRAINTS 74
5.2.2.1 High cost of installation and maintenance of vascular access devices 74
5.2.2.2 Rising product recalls and failures 74
5.2.3 OPPORTUNITIES 75
5.2.3.1 Technological advancements 75
5.2.3.2 Increasing number of hospitals and expanding patient pool 75
5.2.4 CHALLENGES 76
5.2.4.1 Shortage of skilled healthcare professionals 76
5.2.4.2 Risks associated with use of vascular access devices 76
5.3 TECHNOLOGY ANALYSIS 77
5.3.1 KEY TECHNOLOGIES 77
5.3.1.1 Imaging and navigation technologies 77
5.3.1.2 Catheter securement and stabilization technologies 77
5.3.2 COMPLEMENTARY TECHNOLOGIES 77
5.3.2.1 AI and ML 77
5.3.3 ADJACENT TECHNOLOGIES 78
5.3.3.1 Infection control technologies 78
5.4 INDUSTRY TRENDS 78
5.4.1 MINIMALLY INVASIVE VASCULAR ACCESS PROCEDURES 78
5.4.2 INNOVATIONS IN CATHETER MATERIALS AND COATINGS 78
5.5 VALUE CHAIN ANALYSIS 79
5.6 ECOSYSTEM ANALYSIS 80
5.6.1 ROLE IN ECOSYSTEM 81
5.7 SUPPLY CHAIN ANALYSIS 82

5.8 TRADE ANALYSIS 83
5.8.1 IMPORT DATA FOR HS CODE 901839 83
5.8.2 EXPORT DATA FOR HS CODE 901839 84
5.9 PORTER’S FIVE FORCES ANALYSIS 85
5.9.1 THREAT OF NEW ENTRANTS 87
5.9.2 THREAT OF SUBSTITUTES 87
5.9.3 BARGAINING POWER OF BUYERS 87
5.9.4 BARGAINING POWER OF SUPPLIERS 87
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 87
5.10 KEY STAKEHOLDERS & BUYING CRITERIA 88
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 88
5.10.2 KEY BUYING CRITERIA 89
5.11 REGULATORY ANALYSIS 89
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 90
5.11.2 REGULATORY FRAMEWORK 92
5.11.2.1 North America 92
5.11.2.1.1 US 92
5.11.2.1.2 Canada 92
5.11.2.2 Europe 93
5.11.2.3 Asia Pacific 93
5.11.2.4 Latin America 93
5.11.2.5 Middle East & Africa 94
5.12 PATENT ANALYSIS 94
5.12.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 94
5.13 PRICING ANALYSIS 96
5.13.1 INDICATIVE PRICING TREND OF VASCULAR ACCESS DEVICES,
BY KEY PLAYER, 2021–2023 96
5.13.2 INDICATIVE PRICING TREND OF VASCULAR ACCESS DEVICES,
BY REGION, 2021–2023 97
5.14 KEY CONFERENCES & EVENTS, 2025–2026 98
5.15 ADJACENT MARKET ANALYSIS 99
5.15.1 VASCULAR CLOSURE DEVICES MARKET 99
5.16 UNMET NEEDS/END-USER EXPECTATIONS 100
5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 101
5.18 INVESTMENT & FUNDING SCENARIO 101
5.19 IMPACT OF AI/GEN AI ON VASCULAR ACCESS DEVICES MARKET 102
6 VASCULAR ACCESS DEVICES MARKET, BY TYPE 104
6.1 INTRODUCTION 105
6.2 CENTRAL VENOUS ACCESS DEVICES 105
6.2.1 PERIPHERALLY INSERTED CENTRAL CATHETERS 108
6.2.1.1 Better durability and increased clinical utility for extended treatment plans to drive segment 108
6.2.2 TUNNELED CATHETERS 110
6.2.2.1 Lower risk of infection and superior longevity to support
segment growth 110
6.2.3 NON-TUNNELED CATHETERS 112
6.2.3.1 Non-tunneled catheters to be used in critical cases with limited peripheral access 112
6.2.4 IMPLANTABLE PORTS 114
6.2.4.1 Implantable conventional ports 117
6.2.4.1.1 Ability to provide reliable venous access with minimal maintenance to spur adoption 117
6.2.4.2 Implantable power injectable ports 119
6.2.4.2.1 Ability to accommodate high-flow fluids and increased demand for chemotherapy to propel market growth 119
6.3 PERIPHERAL VASCULAR ACCESS DEVICES 121
6.3.1 PERIPHERAL VENOUS ACCESS DEVICES 124
6.3.1.1 Peripheral intravenous catheters 127
6.3.1.1.1 Cost-effectiveness, ease of placement, and compatibility with different treatments to augment segment growth 127
6.3.1.2 Midline catheters 129
6.3.1.2.1 Ability to provide reliable medium-term intravenous access from one to four weeks to aid segment growth 129
6.3.1.3 Butterfly/Winged steel needles 131
6.3.1.3.1 Precision and comfort in short-term venous access procedures to drive segment 131
6.3.2 PERIPHERAL ARTERIAL ACCESS DEVICES 133
6.3.2.1 Critical role in continuous hemodynamic monitoring and blood sampling in acute care settings to propel segment growth 133
6.4 ACCESSORIES 135
6.4.1 NEED FOR ENHANCED FUNCTIONALITY, PATIENT SAFETY, AND PROCEDURAL EFFICIENCY TO DRIVE MARKET 135
6.5 INTRAOSSEOUS VASCULAR ACCESS DEVICES 137
6.5.1 CRITICAL ROLE IN EMERGENCY SITUATIONS TO FUEL UPTAKE IN HIGH-STRESS HEALTHCARE FACILITIES 137
7 VASCULAR ACCESS DEVICES MARKET, BY ROUTE OF INSERTION 140
7.1 INTRODUCTION 141
7.2 INTRAVENOUS ROUTE OF INSERTION 141
7.2.1 RISING NEED FOR ADMINISTERING ESSENTIAL TREATMENTS DURING ACUTE CARE TO AID MARKET GROWTH 141
7.3 SUBCUTANEOUS ROUTE OF INSERTION 143
7.3.1 REDUCED INFECTION RISK, BETTER PATIENT COMFORT, AND MINIMAL MAINTENANCE TO AUGMENT MARKET GROWTH 143

7.4 INTRAOSSEOUS ROUTE OF INSERTION 145
7.4.1 NEED FOR RAPID AND RELIABLE ACCESS IN CRITICAL EMERGENCIES
TO FUEL UPTAKE 145
8 VASCULAR ACCESS DEVICES MARKET, BY APPLICATION 148
8.1 INTRODUCTION 149
8.2 DRUG ADMINISTRATION 150
8.2.1 CHEMOTHERAPY 152
8.2.1.1 Increased incidence of cancer and advancements in oncology care to drive segment 152
8.2.2 OTHER DRUG ADMINISTRATION 154
8.3 FLUID & NUTRITION ADMINISTRATION 156
8.3.1 INCREASING NEED FOR INTRAVENOUS THERAPY IN CHRONIC DISEASES TO SPUR MARKET GROWTH 156
8.4 BLOOD TRANSFUSION 158
8.4.1 FREQUENT NEED FOR BLOOD TRANSFUSION FOR THALASSEMIA AND LYMPHOMA TO BOOST MARKET GROWTH 158
8.5 DIAGNOSTICS & TESTING 160
8.5.1 INCREASING RELIANCE ON ACCURATE DIAGNOSTIC IMAGING, FLUID TESTING, AND PATIENT MONITORING TO AID MARKET GROWTH 160
9 VASCULAR ACCESS DEVICES MARKET, BY END USER 163
9.1 INTRODUCTION 164
9.2 HOSPITALS 164
9.2.1 PUBLIC HOSPITALS 165
9.2.1.1 Increasing demand for affordable healthcare services in emerging economies to drive segment 165
9.2.2 PRIVATE HOSPITALS 167
9.2.2.1 Rising demand for advanced healthcare services and high-quality treatment options to drive market 167
9.3 CLINICS & AMBULATORY CARE CENTERS 169
9.3.1 INCREASING DEMAND FOR OUTPATIENT PROCEDURES AND COST-EFFECTIVE TREATMENTS TO BOOST SEGMENT GROWTH 169
9.4 OTHER END USERS 171
10 VASCULAR ACCESS DEVICES MARKET, BY REGION 174
10.1 INTRODUCTION 175
10.2 NORTH AMERICA 178
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 178
10.2.2 US 187
10.2.2.1 US to dominate North American vascular access devices market during forecast period 187
10.2.3 CANADA 194
10.2.3.1 Rising cancer prevalence and advanced research initiatives to
propel market growth 194
10.3 EUROPE 202
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 202
10.3.2 GERMANY 210
10.3.2.1 Rising obesity rates and growing geriatric population to augment market growth 210
10.3.3 UK 217
10.3.3.1 Increased disease burden to fuel uptake for advanced vascular access devices for better treatment procedures 217
10.3.4 FRANCE 224
10.3.4.1 Presence of vascular access device manufacturers and technological advancements to fuel market growth 224
10.3.5 ITALY 231
10.3.5.1 Strong government healthcare policies to boost market growth 231
10.3.6 SPAIN 238
10.3.6.1 Growing geriatric population and rising incidence of chronic diseases to fuel market growth 238
10.3.7 REST OF EUROPE 244
10.4 ASIA PACIFIC 252
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 252
10.4.2 CHINA 261
10.4.2.1 Advanced healthcare infrastructure and high geriatric population to support market growth 261
10.4.3 INDIA 269
10.4.3.1 Rising governmental health expenditure and increasing incidence of chronic diseases to fuel market growth 269
10.4.4 JAPAN 276
10.4.4.1 Increased geriatric population and high prevalence of cancer to drive market 276
10.4.5 AUSTRALIA 283
10.4.5.1 Increased demand for hemodialysis and advancements in healthcare infrastructure to propel market growth 283
10.4.6 SOUTH KOREA 290
10.4.6.1 Rising burden of chronic diseases and increasing aged population to boost market growth 290
10.4.7 REST OF ASIA PACIFIC 298
10.5 LATIN AMERICA 305
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 305
10.5.2 BRAZIL 313
10.5.2.1 Growing cancer burden and rising need for long-term treatment for chronic patients to drive market 313
10.5.3 MEXICO 320
10.5.3.1 Increasing focus on dialysis for patients with chronic kidney diseases to drive adoption of advanced vascular access devices 320
10.5.4 REST OF LATIN AMERICA 327

10.6 MIDDLE EAST & AFRICA 334
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 334
10.6.2 GCC COUNTRIES 342
10.6.2.1 Increasing healthcare investments and rising prevalence of chronic diseases to propel market growth 342
10.6.3 REST OF MIDDLE EAST & AFRICA 349
11 COMPETITIVE LANDSCAPE 357
11.1 INTRODUCTION 357
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 357
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN VASCULAR ACCESS DEVICES MARKET 357
11.3 REVENUE ANALYSIS, 2019–2023 359
11.4 MARKET SHARE ANALYSIS, 2023 360
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 362
11.5.1 STARS 362
11.5.2 EMERGING LEADERS 362
11.5.3 PERVASIVE PLAYERS 362
11.5.4 PARTICIPANTS 363
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 364
11.5.5.1 Company footprint 364
11.5.5.2 Region footprint 365
11.5.5.3 Type footprint 366
11.5.5.4 Route of insertion footprint 367
11.5.5.5 Application footprint 368
11.5.5.6 End-user footprint 369
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 370
11.6.1 PROGRESSIVE COMPANIES 370
11.6.2 RESPONSIVE COMPANIES 370
11.6.3 DYNAMIC COMPANIES 370
11.6.4 STARTING BLOCKS 370
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 372
11.6.5.1 Detailed list of key startup/SME players 372
11.6.5.2 Competitive benchmarking of key emerging players/startups 373
11.7 COMPANY VALUATION & FINANCIAL METRICS 373
11.7.1 FINANCIAL METRICS 373
11.7.2 COMPANY VALUATION 374
11.8 BRAND/PRODUCT COMPARISON 375
11.9 COMPETITIVE SCENARIO 376
11.9.1 PRODUCT LAUNCHES & APPROVALS 376
11.9.2 DEALS 377
11.9.3 OTHER DEVELOPMENTS 377
12 COMPANY PROFILES 378
12.1 KEY PLAYERS 378
12.1.1 BECTON, DICKINSON AND COMPANY 378
12.1.1.1 Business overview 378
12.1.1.2 Products offered 379
12.1.1.3 Recent developments 384
12.1.1.3.1 Deals 384
12.1.1.4 MnM view 385
12.1.1.4.1 Key strengths 385
12.1.1.4.2 Strategic choices 385
12.1.1.4.3 Weaknesses & competitive threats 385
12.1.2 TELEFLEX INCORPORATED 386
12.1.2.1 Business overview 386
12.1.2.2 Products offered 387
12.1.2.3 Recent developments 390
12.1.2.3.1 Product launches 390
12.1.2.3.2 Other developments 391
12.1.2.4 MnM view 391
12.1.2.4.1 Key strengths 391
12.1.2.4.2 Strategic choices 391
12.1.2.4.3 Weaknesses & competitive threats 391
12.1.3 ICU MEDICAL 392
12.1.3.1 Business overview 392
12.1.3.2 Products offered 393
12.1.3.3 Recent developments 396
12.1.3.3.1 Deals 396
12.1.3.4 MnM view 396
12.1.3.4.1 Key strengths 396
12.1.3.4.2 Strategic choices 396
12.1.3.4.3 Weaknesses & competitive threats 396
12.1.4 NIPRO 397
12.1.4.1 Business overview 397
12.1.4.2 Products offered 398
12.1.4.3 MnM view 399
12.1.4.3.1 Key strengths 399
12.1.4.3.2 Strategic choices 399
12.1.4.3.3 Weaknesses & competitive threats 399
12.1.5 ANGIODYNAMICS, INC. 400
12.1.5.1 Business overview 400
12.1.5.2 Products offered 401
12.1.5.3 Recent developments 402
12.1.5.3.1 Product approvals 402
12.1.5.3.2 Deals 402
12.1.5.4 MnM view 403
12.1.5.4.1 Key strengths 403
12.1.5.4.2 Strategic choices 403
12.1.5.4.3 Weaknesses & competitive threats 403
12.1.6 VYGON 404
12.1.6.1 Business overview 404
12.1.6.2 Products offered 404
12.1.7 TERUMO CORPORATION 411
12.1.7.1 Business overview 411
12.1.7.2 Products offered 413
12.1.8 MEDTRONIC PLC 414
12.1.8.1 Business overview 414
12.1.8.2 Products offered 415
12.1.9 COOK 417
12.1.9.1 Business overview 417
12.1.9.2 Products offered 417
12.1.10 B. BRAUN SE 419
12.1.10.1 Business overview 419
12.1.10.2 Products offered 420
12.1.10.3 Recent developments 425
12.1.10.3.1 Product launches & approvals 425
12.1.10.3.2 Deals 426
12.1.11 MERIT MEDICAL SYSTEMS, INC. 427
12.1.11.1 Business overview 427
12.1.11.2 Products offered 428
12.1.11.3 Recent developments 429
12.1.11.3.1 Deals 429
12.1.12 AMECATH 430
12.1.12.1 Business overview 430
12.1.12.2 Products offered 430
12.1.13 MEDICAL COMPONENTS, INC. 433
12.1.13.1 Business overview 433
12.1.13.2 Products offered 433
12.1.14 HEALTHLINE MEDICAL PRODUCTS 436
12.1.14.1 Business overview 436
12.1.14.2 Products offered 436
12.1.15 ACCESS VASCULAR, INC. 438
12.1.15.1 Business overview 438
12.1.15.2 Products offered 438

12.2 OTHER PLAYERS 439
12.2.1 ARGON MEDICAL DEVICES 439
12.2.2 PAKUMEDMEDICAL PRODUCTS GMBH 440
12.2.3 GUANGDONG BAIHE MEDICAL TECHNOLOGY CO., LTD. 441
12.2.4 PFM MEDICAL GMBH 442
12.2.5 MEDI-TECH DEVICES PVT. LTD. 443
12.2.6 KIMAL 444
12.2.7 POLYMEDICURE 445
12.2.8 DELTAMED 446
12.2.9 NEWTECH MEDICAL DEVICES PVT. LTD. 447
12.2.10 SHANGHAI PUYI MEDICAL INSTRUMENTS CO., LTD. 448
13 APPENDIX 449
13.1 DISCUSSION GUIDE 449
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 457
13.3 CUSTOMIZATION OPTIONS 459
13.4 RELATED REPORTS 459
13.5 AUTHOR DETAILS 460